Vitrakvi Solution, Concentrate
Product Images NDC 50419-393

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Vitrakvi (NDC 50419-393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 100 mg Carton Principal Panel (60 capsules)

VITRAKVI® capsules contain 100mg of larotrectinib sulfate equivalent to 123mg of larotrectinib. These capsules are intended for oral use and are available in a package of 60 capsules.*

FDA Label Image

Image Of 25 mg Carton Principal Panel (60 capsules)

VITRAKVI is an oral medication that comes in the form of capsules containing 25 mg of larotrectinib, which is equivalent to 30.7 mg of larotrectinib sulfate. This medication is intended for oral use and is available in a package of 60 capsules.*

FDA Label Image

Image Of 20 mg/ml Carton Principal Panel (100 mL oral solution)

VITRAKVI® is an oral solution medication containing 20mg/mL of larotrectinib. Each bottle has a total of 100mL of the solution, equivalent to 24.6mg/mL of larotrectini sulfate. This medication is intended for oral use.*

FDA Label Image

Image Of The Chemical Structure Of Vitrakvi (Chem Struct)

FDA Label Image

Image Of Supplies Needed To Take Or Give A Dose Of Vitrakvi Oral Solution (Fig A)

The text contains a description of medical equipment including an oral syringe with a capacity of 5mL, a bottle and a bottle adaptor. A figure labeled as A is present.*

FDA Label Image

Image Of How To Open The Bottle (Fig B)

FDA Label Image

Image Of How To Insert The Adaptor Into The Bottle (Fig C)

FDA Label Image

Image Of The Oral Syringe And A Close Up Of The Markings In mL (Fig D)

FDA Label Image

Image Of Of How To Insert The Oral Syringe Into The Bottle (Fig E)

FDA Label Image

Image Of How To Draw Vitrakvi Into The Oral Syringe For Proper Dose (Fig F)

FDA Label Image

Image Of How To Expell Air Bubbles In The Oral Syringe (Fig G)

FDA Label Image

Image Of How To Remove The Oral Syringe From The Bottle (Fig H)

FDA Label Image

Image Of How To Properly Press The Plunger To Deliver The Dose (Fig I)

FDA Label Image

Image Of Recapping The Bottle (Fig J)

FDA Label Image

Image Of Removing The Plunger From The Barrel Of The Oral Syringe (Fig K)

FDA Label Image

Image Of Rinsing The Oral Syringe (plunger And Barrel) (Fig L)

FDA Label Image

Image Of Re-insertion Of Plunger Into Oral Syringe Barrel (Fig M)

FDA Label Image

Image Of Cleaning Oral Syringe Using Warm Water (Fig N)

FDA Label Image

Image Of Rinsing The Plunger And Barrel Of The Oral Syringe A 2nd Time (Fig O)

FDA Label Image

Image Of Shaking Excess Water From The Barrel And Plunger (Fig P)

FDA Label Image

Image Of Where To Write The Date Of When The Bottle Was Opened (Fig Q)

FDA Label Image

Image Of 100 mg Label Principal Panel (60 capsules)

This is a prescription medication with the brand name VITRAKVI®. The drug comes in capsule form and each capsule contains 100mg of the active ingredient called Larotrectinib. The recommended dosage is provided within the prescribing information. The medication is packaged in a bottle containing 60 capsules and should be kept away from children. It is to be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permitted excursions ranging from 15°C to 30°C (59°F to 86°F). The manufacturer of this medication is Bayer HealthCare Pharmaceuticals Inc.*

FDA Label Image

Image Of 25 mg Label Principal Panel (60 capsules)

This text provides information about VITRAKVI®, which is a capsule medication with the active ingredient Larotrectinib. It also mentions the NDC code (50419-390-01) and provides some precautions for use. There is a statement about keeping it out of reach of children and the recommended storage temperature. The text indicates that prescription information should be consulted for further details. The manufacturer is identified as BayrHeathCoePamacuticss, located at 7381 sasesers.*

FDA Label Image

Image Of 20 mg/ml Label Principal Panel (100 mL oral solution)

NDC 50419-392-01 is a medication called VITRAKVI® in the form of an oral solution with a concentration of 20 mg/mL. However, no further information is available in the text provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.